NEURONAL DEFENSE
Live / Applied — Non-final action mailed (as of 19 Feb 2026)
What this means for you
Not registered yet, but its 24 Sept 2025 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99409682
- Mark type
- Stylized text
- Filed
- 24 Sept 2025
- Attorney of record
- Monte L. Falcoff
Goods and services
- Class 005 — Pharmaceuticals: Natural dietary supplements comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function; Pharmaceutical preparations comprising nanomicellar veterinary formulations of phenylpropyl silanetriol (PTS) carriers in combination with bioactive compounds for use in companion animals for supporting cognitive function, memory, learning ability and neural health in aging animals, mitigating oxidative stress and neuroinflammation associated with neurodegenerative processes, protecting and promoting survival of dopaminergic neurons in toxin-induced models of Parkinson-type and other neurodegenerations, providing prophylactic and therapeutic neuroprotection against environmental and endogenous neurotoxins, supporting nerve regeneration ; and repair following trauma, surgery or peripheral neuropathy, alleviating chemotherapy-induced neurotoxicity, including cisplatin-related peripheral neuropathy, supporting motor coordination, balance and reduction of gait abnormalities, modulating systemic inflammatory responses and supporting central cardiovascular regulatory mechanisms in endotoxemia and SIRS models, maintaining cardiovascular health through antioxidant and anti-inflammatory actions, promoting ocular health by protecting retinal neurons from oxidative damage, providing adaptogenic support to reduce stress, anxiety and behavioral disorders, and supporting gut-brain axis homeostasis to indirectly influence mood and neural function.
Owner
- SoluPet Inc., Toronto, ON, CA
Prosecution history
- 19 Feb 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Feb 2026 — NON-FINAL ACTION E-MAILED
- 19 Feb 2026 — NON-FINAL ACTION WRITTEN
- 30 Jan 2026 — ASSIGNED TO EXAMINER
- 16 Nov 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 16 Nov 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 16 Nov 2025 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 24 Sept 2025 — APPLICATION FILING RECEIPT MAILED
- 24 Sept 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 24 Sept 2025 — NEW APPLICATION ENTERED